SK bioscienceLtd Past Earnings Performance
Past criteria checks 0/6
SK bioscienceLtd's earnings have been declining at an average annual rate of -150.5%, while the Biotechs industry saw earnings growing at 2.7% annually. Revenues have been declining at an average rate of 47.9% per year.
Key information
-150.5%
Earnings growth rate
-152.9%
EPS growth rate
| Biotechs Industry Growth | 11.7% |
| Revenue growth rate | -47.9% |
| Return on equity | -2.5% |
| Net Margin | -21.5% |
| Last Earnings Update | 30 Sep 2024 |
Revenue & Expenses Breakdown
How SK bioscienceLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 201,300 | -43,274 | 66,665 | 75,545 |
| 30 Jun 24 | 371,479 | 27,435 | 63,455 | 81,769 |
| 31 Mar 24 | 371,179 | 22,868 | 62,713 | 86,878 |
| 31 Dec 23 | 369,506 | 22,318 | 60,812 | 85,743 |
| 30 Sep 23 | 419,202 | 45,890 | 66,416 | 84,389 |
| 30 Jun 23 | 278,429 | 18,276 | 64,664 | 76,951 |
| 31 Mar 23 | 390,231 | 80,378 | 63,357 | 61,780 |
| 31 Dec 22 | 456,726 | 122,452 | 61,780 | 57,960 |
| 31 Dec 21 | 929,001 | 355,139 | 46,018 | 47,250 |
Quality Earnings: A302440 is currently unprofitable.
Growing Profit Margin: A302440 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if A302440's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare A302440's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A302440 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (7.9%).
Return on Equity
High ROE: A302440 has a negative Return on Equity (-2.52%), as it is currently unprofitable.